Literature DB >> 22960547

Amniotic fluid stem cells to study mTOR signaling in differentiation.

Margit Rosner1, Katharina Schipany, Bharanidharan Shanmugasundaram, Gert Lubec, Oliver Brandau, Markus Hengstschläger.   

Abstract

The protein kinase mTOR is the central player within a pathway, which is known to be involved in the regulation of e.g., cell size, cell cycle, apoptosis, autophagy, aging and differentiation. mTOR activity responds to many signals, including cellular stress, oxygen, nutrient availability, energy status and growth factors. Deregulation of this enzyme is causatively involved in the molecular development of monogenic human diseases, cancer, obesity, type 2 diabetes or neurodegeneration. Recently, mTOR has also been demonstrated to control stem cell homeostasis. A more detailed investigation of this new mTOR function will be of highest relevance to provide more explicit insights into stem cell regulation in the near future. Different cellular tools, including adult stem cells, embryonic stem cells or induced pluripotent stem cells could be used to investigate the role of mTOR in mammalian stem cell biology. Here we discuss the potential of amniotic fluid stem cells to become a promising cellular model to study the role of signaling cascades in stem cell homeostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960547      PMCID: PMC3527322          DOI: 10.4161/org.22038

Source DB:  PubMed          Journal:  Organogenesis        ISSN: 1547-6278            Impact factor:   2.500


  61 in total

1.  Neurogenic cells in human amniotic fluid.

Authors:  Andrea-Romana Prusa; Erika Marton; Margit Rosner; Dieter Bettelheim; Gent Lubec; Arnold Pollack; Gerhard Bernaschek; Markus Hengstschläger
Journal:  Am J Obstet Gynecol       Date:  2004-07       Impact factor: 8.661

2.  Stem cell marker expression in human trisomy 21 amniotic fluid cells and trophoblasts.

Authors:  A R Prusa; E Marton; M Rosner; A Freilinger; G Bernaschek; M Hengstschläger
Journal:  J Neural Transm Suppl       Date:  2003

3.  Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol.

Authors:  Ming-Song Tsai; Jia-Ling Lee; Yu-Jen Chang; Shiaw-Min Hwang
Journal:  Hum Reprod       Date:  2004-04-22       Impact factor: 6.918

Review 4.  Amniotic fluid stem cell-based models to study the effects of gene mutations and toxicants on male germ cell formation.

Authors:  Claudia Gundacker; Helmut Dolznig; Mario Mikula; Margit Rosner; Oliver Brandau; Markus Hengstschläger
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

Review 5.  An emerging role for TOR signaling in mammalian tissue and stem cell physiology.

Authors:  Ryan C Russell; Chong Fang; Kun-Liang Guan
Journal:  Development       Date:  2011-08       Impact factor: 6.868

6.  Tuberin and PRAS40 are anti-apoptotic gatekeepers during early human amniotic fluid stem-cell differentiation.

Authors:  Christiane Fuchs; Margit Rosner; Helmut Dolznig; Mario Mikula; Nina Kramer; Markus Hengstschläger
Journal:  Hum Mol Genet       Date:  2011-11-16       Impact factor: 6.150

7.  Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research?

Authors:  Andrea-Romana Prusa; Erika Marton; Margit Rosner; Gerhard Bernaschek; Markus Hengstschläger
Journal:  Hum Reprod       Date:  2003-07       Impact factor: 6.918

8.  mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells.

Authors:  Mirei Murakami; Tomoko Ichisaka; Mitsuyo Maeda; Noriko Oshiro; Kenta Hara; Frank Edenhofer; Hiroshi Kiyama; Kazuyoshi Yonezawa; Shinya Yamanaka
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 9.  Amniotic fluid cells and human stem cell research: a new connection.

Authors:  Andrea-Romana Prusa; Markus Hengstschlager
Journal:  Med Sci Monit       Date:  2002-11

10.  Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis.

Authors:  Margit Rosner; Helmut Dolznig; Katharina Schipany; Mario Mikula; Oliver Brandau; Markus Hengstschläger
Journal:  Oncotarget       Date:  2011-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.